Cargando…
Structural basis for differential p19 targeting by IL-23 biologics
BACKGROUND: IL-23 is central to the pathogenesis of psoriasis, and is structurally comprised of p19 and p40 subunits. “Targeted” IL-23 inhibitors risankizumab, tildrakizumab, and guselkumab differ mechanistically from ustekinumab because they bind p19, whereas ustekinumab binds p40; however, a knowl...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cold Spring Harbor Laboratory
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029002/ https://www.ncbi.nlm.nih.gov/pubmed/36945513 http://dx.doi.org/10.1101/2023.03.09.531913 |